Introduction {#tca12424-sec-0005}
============

Visceral pleural invasion (VPI) has been recognized as an adverse prognostic factor in non‐small cell lung cancer (NSCLC) patients, and is included in the tumor node metastasis (TNM) staging system.[1](#tca12424-bib-0001){ref-type="ref"} For NSCLC tumors sized 3 cm or less, the presence of VPI increases the T stage from T1 to T2.[1](#tca12424-bib-0001){ref-type="ref"}, [2](#tca12424-bib-0002){ref-type="ref"}

Pleural invasion is classified into the following: PL0, tumor with no pleural involvement beyond its elastic layer; PL1, tumor that invades beyond the elastic layer of the visceral pleura but is not exposed on the pleural surface; PL2, tumor that invades to the pleural surface; and PL3, tumor that invades to the parietal pleura.[2](#tca12424-bib-0002){ref-type="ref"} Therefore, PL0 is not classified as VPI, while PL3 is classified as chest wall invasion as is associated with parietal pleural invasion. Although classified separately, PL1 and PL2 are both interpreted as VPI in the TNM staging system. Previous studies have reported that patients with PL2 have significantly poorer postoperative survival outcomes than those with PL1.[3](#tca12424-bib-0003){ref-type="ref"}, [4](#tca12424-bib-0004){ref-type="ref"} It has also been reported that the percentage of pleural recurrence in PL2 groups is significantly higher than in PL1 groups.[3](#tca12424-bib-0003){ref-type="ref"}

Therefore, the aim of this study was to compare the prognostic value of the extent of VPI in patients with resected node‐negative NSCLC. We also focused on patterns of recurrence, particularly the presence of ipsilateral pleural recurrence.

Methods {#tca12424-sec-0006}
=======

Patients {#tca12424-sec-0007}
--------

This study was a retrospective review and analysis of the lung cancer database. All enrolled patients had undergone curative surgical resection at Kyungpook National University Medical Center between January 2012 and May 2015 and were pathologically diagnosed with node‐negative NSCLC. Patients with lymph node metastases were excluded from the analysis in order to focus on the relationship between the extent of VPI and survival outcomes. Patients with no VPI (PL0) or parietal pleural invasion (PL3) were also excluded. None of the patients in this study had received neoadjuvant therapy.

Pathology {#tca12424-sec-0008}
---------

Visceral pleural invasion was examined in tumor sections with hematoxylin and eosin staining. Van Gieson staining was performed if the VPI status (PL1 or PL2) was unclear with hematoxylin and eosin staining alone. VPI was classified according to the revised International Union Against Cancer and American Joint Committee on Cancer TNM classification.[2](#tca12424-bib-0002){ref-type="ref"} Lymphatic and vascular involvement were also examined.

Statistical analysis {#tca12424-sec-0009}
--------------------

The patients were divided into two groups based on the extent of VPI (PL1 and PL2). Fisher\'s exact and χ^2^ tests were used to assess the differences in the categorical variables between the two groups. Shapiro--Wilk and Mann--Whitney tests were used for discrete and continuous variables. Overall survival (OS) was defined as the interval between the date of surgical resection and the date of either death or the last follow‐up. Disease‐free survival (DFS) was calculated from the date of surgical resection to the date of diagnosis of first recurrence. The OS and DFS rates were calculated using the Kaplan--Meier method. Univariate and multivariate analyses were performed using a Cox proportional hazards regression model. VPI extent and variables that showed statistical significance on univariate analysis were included in multivariate analysis. Statistical analyses were performed using SPSS version 23.0 (IBM Corp., Chicago, IL, United States). All *P* values less than 0.05 were defined as statistically significant.

Results {#tca12424-sec-0010}
=======

This study included 90 patients with surgically resected NSCLC with VPI (PL1 or PL2). All patients were pathologically diagnosed with node‐negative NSCLC and were divided into two groups based on the extent of VPI (PL1 vs. PL2). PL1 was identified in 73 patients. No significant differences were found between PL1 and PL2 groups in age, gender, smoking history, type of surgery, and comorbidities. The mean follow‐up periods for both groups were around 23 months (Table [1](#tca12424-tbl-0001){ref-type="table-wrap"}).

###### 

Patient characteristics

  Variables                        PL1 group (*n* = 73)   PL2 group (*n* = 17)   *P*
  -------------------------------- ---------------------- ---------------------- -------
  Mean age (years)                 68.3 ± 9.0             64.4 ± 8.4             0.093
  Gender                                                                         0.430
  Male                             44 (60.3)              12 (70.6)              
  Female                           29 (39.7)              5 (29.4)               
  Smoking                                                                        0.832
  Never                            36 (49.3)              7 (41.2)               
  Ex                               22 (30.1)              6 (35.3)               
  Current                          15 (20.5)              4 (23.5)               
  Pack‐year index                                                                0.704
  ≤20                              11                     4                      
  \>20                             26                     6                      
  CEA, ng/mL†                                                                    0.881
  \<3                              40 (64.5)              10 (62.5)              
  ≥3                               22 (35.5)              6 (37.5)               
  Operation                                                                      0.255
  Lobectomy                        68 (93.2)              15 (88.2)              
  Bilobectomy                      0                      1 (5.9)                
  Limited resection                5 (6.8)                1 (5.9)                
  Hypertension                                                                   0.224
  Absence                          50 (68.5)              9 (52.9)               
  Presence                         23 (31.5)              8 (47.1)               
  Diabetes mellitus                                                              0.518
  Absence                          58 (79.5)              12 (70.6)              
  Presence                         15 (20.5)              5 (29.4)               
  Tuberculosis                                                                   0.471
  Absence                          71 (97.3)              16 (94.1)              
  Presence                         2 (2.7)                1 (5.9)                
  CAD                                                                            0.579
  Absence                          68 (93.2)              17 (100)               
  Presence                         5 (6.8)                0                      
  CVA                                                                            1.000
  Absence                          65 (89)                16 (94.1)              
  Presence                         8 (11)                 1 (5.9)                
  Mean follow‐up period (months)   23.8 ± 11.8            22.4 ± 11.0            0.620

Data are lacking in some patients for this variable.

CAD, coronary artery disease; CEA, carcinoembryonic antigen; CVA, cerebral vascular accident.

Of the 73 patients in the PL1 group, adenocarcinoma was the most common histologic type (48 cases, 65.8%). According to tumor size, there were 22 cases ≤20 mm (30.1%), 21 cases \>20 to ≤30 mm (28.8%), 24 cases \>30 to ≤50 mm (32.9%), and six cases \>50 to ≤70 mm (8.2%). Lymphatic invasion was identified in 12 patients (16.4%), and vascular invasion was identified in eight (11.0%). Of the 17 patients in the PL2 group, there was no significant difference in the pathologic findings including the histologic type, tumor size, lymphatic invasion, and vascular invasion compared to the PL1 group (*P* = 0.719, 0.818, 0.448, and 0.344, respectively; Table [2](#tca12424-tbl-0002){ref-type="table-wrap"}).

###### 

Pathologic findings

  Variables                  PL1 group (*n* = 73)   PL2 group (*n* = 17)  *P*
  ------------------------- ---------------------- ---------------------- -------
  Histologic type                                                         0.719
  Squamous cell carcinoma             22                     6            
  Adenocarcinoma                      48                     10           
  Others                              3                      1            
  Tumor size                                                              0.818
  ≤20 mm                              22                     4            
  \>20 to ≤30 mm                      21                     4            
  \>30 to ≤50 mm                      24                     7            
  \>50 to ≤70 mm                      6                      2            
  Lymphatic invasion                                                      0.448
  Absence                             61                     16           
  Presence                            12                     1            
  Vascular invasion                                                       0.344
  Absence                             65                     17           
  Presence                            8                      0            

Among the 90 patients, two cancer‐related deaths occurred (1 patient in each group). The three‐year OS rates for the PL1 and PL2 groups were 97.4% and 82.4%, respectively (*P* = 0.004, Fig [1](#tca12424-fig-0001){ref-type="fig"}). Nineteen recurrences occurred; the recurrence rates were 19.2% (14 of 73 patients) in the PL1 and 29.4% (5 of 17 patients) in the PL2 group. The two‐year DFS rates for the PL1 and PL2 groups were 81.0% and 76.5%, respectively (*P* = 0.419, Fig [2](#tca12424-fig-0002){ref-type="fig"}). Two local recurrences, six distant recurrences, and six both local and distant recurrences developed in the PL1 group. Two local recurrences and three distant recurrences developed in the PL2 group (Table [3](#tca12424-tbl-0003){ref-type="table-wrap"}). There was no significant difference in the patterns of recurrence between the groups (*P* = 0.113). Seven ipsilateral pleural recurrences developed (6 patients in the PL1, 1 in the PL2 group; *P* = 1.000; Table [3](#tca12424-tbl-0003){ref-type="table-wrap"}). Although the patients with PL2 had poorer survival outcomes, univariate analysis indicated that there was no significant difference between the groups based on the extent of VPI (hazard ratio \[HR\] 1.941; 95% confidence interval \[CI\], 0.681--5.528; *P* = 0.214; Table [4](#tca12424-tbl-0004){ref-type="table-wrap"})**.** Multivariate analysis also revealed that DFS was not significantly associated with the extent of VPI (HR 1.753, 95% CI 0.582--5.284; *P* = 0.319; Table [4](#tca12424-tbl-0004){ref-type="table-wrap"}).

![Overall survival curve of patients according to the extent of visceral pleural invasion.](TCA-8-197-g002){#tca12424-fig-0001}

![Disease‐free survival curve of patients according to the extent of visceral pleural invasion.](TCA-8-197-g001){#tca12424-fig-0002}

###### 

Characteristics of recurrence

  Variables                         PL1 (*n* = 73)   PL2 (*n* = 17)  *P*
  -------------------------------- ---------------- ---------------- -------
  Recurrence                                                         0.342
  No                                      59               12        
  Yes                                     14               5         
  Patterns of recurrence                                             0.113
  Local recurrence only                   2                2         
  Distant recurrence only                 6                3         
  Both recurrence                         6                0         
  Ipsilateral pleural recurrence                                     1.000
  Absence                                 67               16        
  Presence                                6                1         
  Disease‐free interval (months)     22.1 ± 11.7      21.8 ± 11.9    0.893

###### 

Univariate and multivariate analyses for disease‐free survival

  Variables                   Univariate   Multivariate                                    
  --------------------------- ------------ --------------- ------- ------- --------------- -------
  Gender                                                                                   
  Male                        1                                    1                       
  Female                      0.212        0.048--0.931    0.040   0.385   0.067--2.198    0.283
  Age                         0.986        0.939--1.036    0.584   0.980   0.929--1.033    0.449
  CEA                                                                                      
  \<3                         1                                                            
  ≥3                          0.371        0.105           1.315                           
  Smoking                                                                                  
  Never                       1                                    1                       
  Ex                          4.740        1.534--14.644   0.007   4.740   1.534--14.644   0.007
  Current                     1.652        0.390--6.993    0.496   1.652   0.390--6.993    0.496
  Pack‐year index                                                                          
  ≤20                         1                                                            
  \>20                        1.152        0.301--4.399    0.836                           
  Operation                                                                                
  Major resection             1                                                            
  Limited resection           0.833        0.110--6.316    0.860                           
  Tumor size                                                                               
  ≤20 mm                      1                                    1                       
  \>20 to ≤30 mm              2.782        0.636--12.165   0.174   2.542   0.548--11.783   0.233
  \>30 to ≤50 mm              3.338        0.837--13.302   0.088   2.860   0.607--13.469   0.184
  \>50 to ≤70 mm              7.347        1.549--34.844   0.012   3.232   0.531--19.681   0.203
  Pathology                                                                                
  SQCC                        1                                                            
  AD                          0.424        0.156--1.151    0.092                           
  Other                       0.966        0.118--7.898    0.974                           
  Visceral pleural invasion                                                                
  PL1                         1                                    1                       
  PL2                         1.941        0.681--5.528    0.214   1.753   0.582--5.284    0.319
  Lymphatic invasion                                                                       
  Absence                     1                                                            
  Presence                    1.821        0.592--5.603    0.296                           
  Vascular invasion                                                                        
  Absence                     1                                                            
  Presence                    0.605        0.080--4.577    0.626                           

AD, adenocarcinoma; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; SQCC, squamous cell carcinoma.

Discussion {#tca12424-sec-0011}
==========

Although the TNM staging system is the most powerful predictor of NSCLC, survival and recurrence rates in NSCLC patients with the same pathologic TNM stage were variable.[5](#tca12424-bib-0005){ref-type="ref"} Therefore, many researchers are currently working on developing a more accurate TNM staging system.

Visceral pleural invasion is one of the important prognostic factors in patients with surgically resected NSCLC,[6](#tca12424-bib-0006){ref-type="ref"} [8](#tca12424-bib-0008){ref-type="ref"} and it is included in the TNM staging system as a factor that upstages the T factor from T1 to T2.[2](#tca12424-bib-0002){ref-type="ref"} VPI is defined as tumor extension beyond the elastic layer of the visceral pleura, regardless of invasion of the pleural surface.[2](#tca12424-bib-0002){ref-type="ref"} If a tumor extends beyond the elastic layer of the visceral pleura but is not exposed on the pleural surface, it is classified as PL1. If a tumor is exposed on the pleural surface but does not involve adjacent anatomic structures, it is classified as PL2. VPI is shown to be associated with extensive mediastinal lymph node metastases, and, thus, poor surgical outcomes.[6](#tca12424-bib-0006){ref-type="ref"}, [9](#tca12424-bib-0009){ref-type="ref"} The higher frequency of mediastinal lymph node metastasis is probably a result of the drainage of cancer cells through the subpleural lymphatics into the mediastinal lymph nodes.[10](#tca12424-bib-0010){ref-type="ref"} Some studies have also demonstrated that VPI is a significant prognostic factor regardless of N status.[7](#tca12424-bib-0007){ref-type="ref"}, [11](#tca12424-bib-0011){ref-type="ref"} Brewer speculated that VPI may lead to diffuse dissemination of cancer cells throughout the pleural cavity by pleural effusion.[12](#tca12424-bib-0012){ref-type="ref"} Previous studies have also reported a close correlation between VPI and malignant pleural effusion.[13](#tca12424-bib-0013){ref-type="ref"}, [14](#tca12424-bib-0014){ref-type="ref"}

The microscopic anatomy of the visceral pleura consists of five layers, although there is some variation in the number and composition.[10](#tca12424-bib-0010){ref-type="ref"} An important anatomical landmark is the elastic layer, consisting of a broader and stronger layer and a thinner inner layer.[10](#tca12424-bib-0010){ref-type="ref"} The visceral pleura contains many lymphatic and blood vessels sandwiched in between these elastic layers.[10](#tca12424-bib-0010){ref-type="ref"}, [15](#tca12424-bib-0015){ref-type="ref"} Therefore, the closer the cancer cells are to the pleural surface, the more likely that they are drained through the subpleural lymphatics, and, hence, the more likely they are to be associated with malignant pleural effusion. Hung *et al.* reported that the overall recurrence rate in patients with PL2 was significantly higher than those with PL1.[3](#tca12424-bib-0003){ref-type="ref"} They also reported that the percentage of pleural recurrence in the PL2 group was significantly higher than in the PL1 group.[3](#tca12424-bib-0003){ref-type="ref"} In their study, all patients had been diagnosed with pathologic node‐negative NSCLC. Kudo *et al.* also reported that the five‐year OS rate in patients with PL2 was significantly poorer than in those with PL1 (*P* = 0.03).[4](#tca12424-bib-0004){ref-type="ref"} On the other hand, Osaki *et al.* reported that no significant survival difference was found between PL1 and PL2 groups (*P* = 0.61).[16](#tca12424-bib-0016){ref-type="ref"} In actual fact, the five‐year OS rate in the PL1 group in Osaki *et al*.\'s study was 43.9%, which was lower than that in their PL2 group (54.9%). Shimizu *et al.* reported that the five‐year OS rates for patients with PL1 or PL2 tumors of 3 cm or less were not significantly different (*P* = 0.20).[17](#tca12424-bib-0017){ref-type="ref"} In their study, the five‐year OS rates for patients with PL1 or PL2 tumors larger than 3 cm were also not significantly different (*P* = 0.47).[17](#tca12424-bib-0017){ref-type="ref"} Adachi *et al.* also found no evidence of a significant survival difference between PL1 and PL2 groups, regardless of the status of lymph node metastasis.[8](#tca12424-bib-0008){ref-type="ref"} In our study, the three‐year OS rate for the PL1 group (97.4%) was significantly higher than that of the PL2 (82.5%) (*P* = 0.004). Although the two‐year DFS rate in the PL1 group (81.0%) was better than that in the PL2 group (76.5%), there was no significant difference between these groups (*P* = 0.419). Considering the anatomy of the visceral pleura, it was thought that lymphatic and vascular invasion would be more common in the PL2 group. However, we found no significant difference between the groups and, in actual fact, lymphatic and vascular invasion was more frequently found in the PL1 group (*P* = 0.448, and 0.344, respectively). Regarding patterns of recurrence, it was hypothesized that ipsilateral pleural recurrence would be more common in the PL2 group. However, there was no significant difference in the ipsilateral pleural recurrence rate between the PL1 and PL2 groups (8.2%, and 5.9%, respectively; *P* = 1.000).

We found that the extent of VPI (PL1 or PL2) was not a significant poor predictor of surgical outcome in node‐negative NSCLC patients after curative resection in both univariate and multivariate analyses. According to our findings, it is valid to use the current TNM classification to assess VPI, even though they do not distinguish between PL1 and PL2.

This study has some limitations. The sample size was small and the follow‐up period was relatively short. Future studies with a larger patient population and longer follow‐up period may allow more precise analysis of cancer‐related death and recurrence.

In conclusion, in patients with pathologic node‐negative NSCLC with VPI, the extent of VPI (PL1 or PL2) was not a significant or independent prognostic factor. Therefore, VPI extent may not influence survival outcomes in patients with node‐negative NSCLC with VPI. The current TNM staging system, which defines both PL1 and PL2 status as VPI, is valid for the assessment of VPI. Our results revealed higher OS and DFS rates in the PL1 than in the PL2 group. Further studies with a larger sample size and longer follow‐up period are required for more precise analysis.
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